gill-leng-380_x_215-1

NICE promotes Professor Gillian Leng as its new Chief Executive

pharmafile | March 18, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK, pharma 

NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng to serve as its new Chief Executive.

She is set to replace current Chief Sir Andrew Dillon who will step down on 1 April, ending his tenure at the organisation he has led since 1999.

Professor Leng steps up from her role as Deputy Chief Executive, a position she has held since 2007, though she also holds the title of Director of Health and Social Care. She was selected for her new role by the non-executive members of NICE’s Board.

Sir Dillon remarked: “I am delighted that Gill has been appointed as NICE’s next Chief Executive. She is an outstanding leader and has all the qualities needed to lead the organisation into its third decade. I am entirely confident that NICE will be safe and successful in her hands.”

Professor Leng also commented on her own appointment: “Under Andrew’s leadership NICE has gained a formidable reputation both nationally and internationally as a world leader in guidance development. I am honoured and privileged to have been appointed as its second Chief Executive. I look forward to working with the Institute’s staff and stakeholders as we enter an exciting new chapter of innovative changes to deliver our portfolio of guidance into the hands of frontline staff in an easy and intuitive way.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

weight-2036971_960_720

UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and …

Latest content